- Home
- MIRM vs RVLV Comparison
MIRM vs RVLV Comparison
Compare MIRM & RVLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- RVLV
- Stock Information
- Founded
- MIRM 2018
- RVLV 2003
- Country
- MIRM United States
- RVLV United States
- Employees
- MIRM N/A
- RVLV N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- RVLV Catalog/Specialty Distribution
- Sector
- MIRM Health Care
- RVLV Consumer Discretionary
- Exchange
- MIRM Nasdaq
- RVLV Nasdaq
- Market Cap
- MIRM 1.9B
- RVLV N/A
- IPO Year
- MIRM 2019
- RVLV 2019
- Fundamental
- Price
- MIRM $40.00
- RVLV $20.80
- Analyst Decision
- MIRM Strong Buy
- RVLV Buy
- Analyst Count
- MIRM 11
- RVLV 14
- Target Price
- MIRM $58.55
- RVLV $28.79
- AVG Volume (30 Days)
- MIRM 447.2K
- RVLV 1.6M
- Earning Date
- MIRM 05-07-2025
- RVLV 05-06-2025
- Dividend Yield
- MIRM N/A
- RVLV N/A
- EPS Growth
- MIRM N/A
- RVLV 81.03
- EPS
- MIRM N/A
- RVLV 0.70
- Revenue
- MIRM $336,888,000.00
- RVLV $1,129,911,000.00
- Revenue This Year
- MIRM $29.51
- RVLV $10.98
- Revenue Next Year
- MIRM $20.27
- RVLV $8.77
- P/E Ratio
- MIRM N/A
- RVLV $29.90
- Revenue Growth
- MIRM 80.76
- RVLV 5.73
- 52 Week Low
- MIRM $23.14
- RVLV $14.88
- 52 Week High
- MIRM $54.23
- RVLV $39.58
- Technical
- Relative Strength Index (RSI)
- MIRM 41.05
- RVLV 47.95
- Support Level
- MIRM $38.22
- RVLV $18.61
- Resistance Level
- MIRM $40.14
- RVLV $21.40
- Average True Range (ATR)
- MIRM 2.24
- RVLV 1.62
- MACD
- MIRM 0.07
- RVLV 0.23
- Stochastic Oscillator
- MIRM 48.50
- RVLV 66.73
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.